AMPLEXOR Life Sciences to Present and Exhibit at Upcoming DIA 2019 Global Annual Meeting
–(BUSINESS WIRE)–AMPLEXOR Life Sciences: MEDIA ADVISORY: The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the…
Pharmaceuticals, Biotechnology and Life Sciences
–(BUSINESS WIRE)–AMPLEXOR Life Sciences: MEDIA ADVISORY: The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the…
Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL Data from…
Steven Horwitz, MD, Gives Oral Presentation Highlighting Phase 1 Duvelisib Data in Patients with Relapsed or Refractory PTCL Data from…
Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.
Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO).
Piramal Pharma Solutions (PPS), has invested $10 million for a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
Kansas-based KCAS, a leading bioanalytical testing laboratory for the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries, said that its Shawnee Mission site, a bioanalytical testing laboratory facility, successfully completed a U.S. Food and Drug Administration (FDA) general re-inspection conducted between June 10 and June 13, 2019. The previous inspection of KCAS took place in 2016.
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.